Semin Thromb Hemost 2014; 40(02): 232-238
DOI: 10.1055/s-0034-1365841
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Factor XIII Assays and Associated Problems for Laboratory Diagnosis of Factor XIII Deficiency: An Analysis of International Proficiency Testing Results

Peihong Hsu
1   Department of Pathology/Laboratory Medicine, Hofstra North Shore-LIJ School of Medicine, Lake Success, New York
,
Nicole D. Zantek
2   Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
,
Piet Meijer
3   ECAT Foundation, Leiden, The Netherlands
,
Catherine P. M. Hayward
4   Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
,
Judith Brody
1   Department of Pathology/Laboratory Medicine, Hofstra North Shore-LIJ School of Medicine, Lake Success, New York
,
Xinmin Zhang
1   Department of Pathology/Laboratory Medicine, Hofstra North Shore-LIJ School of Medicine, Lake Success, New York
,
Kristi J. Smock
5   Department of Pathology and ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories, University of Utah, Salt Lake City, Utah
,
Elizabeth M. Van Cott
6   Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
04 February 2014 (online)

Abstract

We analyzed results from the External quality Control of diagnostic Assays and Tests program to assess current clinical laboratory practice and performance of different methods for factor XIII (FXIII) testing internationally. FXIII proficiency testing data from all eight surveys conducted in 2010 and 2011 were analyzed (1,283 results), comparing the three available methods for detecting FXIII deficiency, thus including clot-solubility qualitative activity, quantitative activity, and antigen. Clot-solubility qualitative assays detected a deficiency in only 16% (11/69) of samples with less than 2% FXIII. Assays using added thrombin detected more deficiencies (33%) than did assays without added thrombin (11%). The most commonly used quantitative activity method tended to produce higher results for low FXIII samples than other quantitative activity methods. Antigen results generally showed good accuracy compared with expected levels. The mean interlaboratory coefficients of variation showed wide variability, especially for samples with less than 10% FXIII activity. Laboratory self-classification of results (as normal vs. abnormal) was good, and was slightly better for specimens with ≤ 25% FXIII than for specimens with 26 to 70% or those with >70% FXIII. We conclude that quantitative activity assays perform better for detecting FXIII deficiency than clot solubility assays, although some quantitative activity assays overestimate low FXIII levels.

 
  • References

  • 1 Lopaciuk S, Lovette KM, McDonagh J, Chuang HY , McDonagh. Subcellular distribution of fibrinogen and factor XIII in human blood platelets. Thromb Res 1976; 8 (4) 453-465
  • 2 Komáromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost 2011; 9 (1) 9-20
  • 3 Muszbek L, Ariëns RA, Ichinose A ; ISTH SSC SUBCOMMITTEE ON FACTOR XIII. Factor XIII: recommended terms and abbreviations. J Thromb Haemost 2007; 5 (1) 181-183
  • 4 Muszbek L, Bagoly Z, Cairo A, Peyvandi F. Novel aspects of factor XIII deficiency. Curr Opin Hematol 2011; 18 (5) 366-372
  • 5 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5: 179-186
  • 6 Kohler HP, Ichinose A, Seitz R, Ariens RAS, Muszbek L ; Factor XIII And Fibrinogen SSC Subcommittee Of The ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9 (7) 1404-1406
  • 7 Hayward CPM, Moffat KA. Laboratory testing for bleeding disorders: strategic uses of high and low-yield tests. Int J Lab Hematol 2013; 35 (3) 322-333
  • 8 Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U ; Study Group. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Semin Thromb Hemost 1996; 22 (5) 415-418
  • 9 Zantek ND, Hsu P, Refaai MA, Ledford-Kraemer M, Meijer P, Van Cott EM. Factor VII assay performance: an analysis of the North American Specialized Coagulation Laboratory Association proficiency testing results. Int J Lab Hematol 2013; 35 (3) 314-321
  • 10 Van Cott EM, Ledford-Kraemer M, Meijer P, Nichols WL, Johnson SM, Peerschke EI ; NASCOLA Proficiency Testing Committee. Protein S assays: an analysis of North American Specialized Coagulation Laboratory Association proficiency testing. Am J Clin Pathol 2005; 123 (5) 778-785
  • 11 Chandler WL, Peerschke EIB, Castellone DD, Meijer P ; NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135 (6) 862-869
  • 12 Hayward CPM, Moffat KA, Plumhoff E , et al. External quality assessment of platelet disorder investigations: results of international surveys on diagnostic tests for dense granule deficiency and platelet aggregometry interpretation. Semin Thromb Hemost 2012; 38 (6) 622-631
  • 13 Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P ; NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2009; 131 (4) 552-558
  • 14 Baron JM, Johnson SM, Ledford-Kraemer MR, Hayward CP, Meijer P, Van Cott EM. Protein C assay performance: an analysis of North American specialized coagulation laboratory association proficiency testing results. Am J Clin Pathol 2012; 137 (6) 909-915
  • 15 Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7 (4) 229-242
  • 16 Schroeder V, Durrer D, Meili E, Schubiger G, Kohler HP. Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterisation in 2005. Swiss Med Wkly 2007; 137 (19–20) 272-278
  • 17 Jakobsen E, Godal HC. Simple, semiquantitative test for partial factor XIII (FSF) deficiency. Scand J Haematol 1974; 12 (5) 366-368
  • 18 Francis JL. The detection and measurement of factor XIII activity: a review. Med Lab Sci 1980; 37 (2) 137-147
  • 19 Jennings I, Kitchen S, Woods TA, Preston FE ; UK NEQAS. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003; 1 (12) 2603-2608
  • 20 Lim W, Moffat K, Hayward CPM. Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. J Thromb Haemost 2004; 2 (6) 1017-1019
  • 21 Ajzner E, Muszbek L. Kinetic spectrophotometric factor XIII activity assays: the subtraction of plasma blank is not omissible [corrected]. J Thromb Haemost 2004; 2 (11) 2075-2077
  • 22 Favaloro EJ, Plebani M, Lippi G. Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing?. Clin Chem Lab Med 2011; 49 (12) 1965-1973
  • 23 Favaloro EJ, Plebani M, Lippi G. Regulation in hemostasis and thrombosis: part I-in vitro diagnostics. Semin Thromb Hemost 2013; 39 (3) 235-249
  • 24 Ivaskevicius V, Seitz R, Kohler HP , et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (6) 914-921
  • 25 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39 (6) 632-641
  • 26 Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35 (4) 426-438